Robert Cook - Castle Biosciences Senior Development
| CSTL Stock | USD 23.74 0.74 3.02% |
Executive
Robert Cook is Senior Development of Castle Biosciences
| Age | 52 |
| Address | 505 South Friendswood Drive, Friendswood, TX, United States, 77546 |
| Phone | 866 788 9007 |
| Web | https://castlebiosciences.com |
Castle Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.0592) % which means that it has lost $0.0592 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0782) %, meaning that it created substantial loss on money invested by shareholders. Castle Biosciences' management efficiency ratios could be used to measure how well Castle Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.17. The value of Return On Capital Employed is expected to slide to -0.17. At this time, Castle Biosciences' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 1.5 M this year, although the value of Net Tangible Assets will most likely fall to about 181.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Amy Rocklin | Neogen | 51 | |
| Scott Gleason | Myriad Genetics | 45 | |
| Stephane Bancel | Qiagen NV | 47 | |
| Samraat Raha | Myriad Genetics | 51 | |
| David Naemura | Neogen | 54 | |
| Bill Waelke | Neogen | N/A | |
| Antonio Santos | Qiagen NV | N/A | |
| Ross Levine | Qiagen NV | 49 | |
| Michael MD | Exagen Inc | 69 | |
| Scott Leffler | Myriad Genetics | 49 | |
| Toralf Haag | Qiagen NV | 54 | |
| Benjamin JD | Sera Prognostics | 45 | |
| Sarah Demey | Neogen | N/A | |
| Austin Aerts | Sera Prognostics | N/A | |
| Elaine Mardis | Qiagen NV | 58 | |
| John Wegener | Exagen Inc | 55 | |
| Thomas Ebeling | Qiagen NV | 61 | |
| William Bauta | bioAffinity Technologies Warran | N/A | |
| Shereen Solaiman | Myriad Genetics | 51 | |
| Glenn Farrell | Myriad Genetics | N/A | |
| JeanPascal Viola | Qiagen NV | N/A | |
Management Performance
| Return On Equity | -0.0782 | ||||
| Return On Asset | -0.0592 |
Castle Biosciences Leadership Team
Elected by the shareholders, the Castle Biosciences' board of directors comprises two types of representatives: Castle Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Castle. The board's role is to monitor Castle Biosciences' management team and ensure that shareholders' interests are well served. Castle Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Castle Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Toby Juvenal, Vice President of Sales | ||
| Camilla Zuckero, Exec Communications | ||
| Derek Maetzold, President CEO, Founder, Director | ||
| John Abbott, VP Controller | ||
| RN RN, Chief Officer | ||
| Kristen RN, Chief Officer | ||
| Tobin Juvenal, Chief Officer | ||
| Kevin Doman, Vice Sales | ||
| Alice Izzo, Senior Marketing | ||
| Matthew MD, Senior Medical | ||
| Keli Greenberg, VP Resources | ||
| Robert Cook, Senior Development | ||
| Frank Stokes, CFO Treasurer | ||
| Bernhard Spiess, Company Secretary |
Castle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Castle Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0782 | ||||
| Return On Asset | -0.0592 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 461.68 M | ||||
| Shares Outstanding | 27.61 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 93.40 % | ||||
| Number Of Shares Shorted | 1.44 M | ||||
| Price To Earning | 87.86 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Castle Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Castle Stock analysis
When running Castle Biosciences' price analysis, check to measure Castle Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Castle Biosciences is operating at the current time. Most of Castle Biosciences' value examination focuses on studying past and present price action to predict the probability of Castle Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Castle Biosciences' price. Additionally, you may evaluate how the addition of Castle Biosciences to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Castle Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share (1.13) | Revenue Per Share 9.279 | Quarterly Revenue Growth 0.736 | Return On Assets (0.06) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.